Article Text

Download PDFPDF
4CPS-154 Follow-up in the use of biotherapies in crohn’s disease in a french university hospital
  1. B Cortes,
  2. M Micol,
  3. MA Esteve,
  4. P Bertault-Peres,
  5. M Roudot
  1. AP-HM, Hôpital de la Timone, Pharmacie, Marseille, France


Background Crohn’s disease is a chronic inflammatory bowel disease. Treatment of outbreaks is based on corticoids, 5-ASA, nutritional support or anti-TNF alpha therapy (adalimumab, infliximab). The first-line background treatment consists in the use of azathioprine, 6-mercaptopurine and methotrexate. If treatment fails, biotherapies such as anti-TNF alpha or vedolizumab are used.

Purpose The aim of this study is to review the use of biotherapies in Crohn’s disease in a French university hospital.

Material and methods Retrospective study of biotherapy prescriptions in Crohn’s disease between 1 March 2016 and 1 March 2017: extraction of data from Computerised Physician Order Entry and pharmacy management software (Pharma®, Computer Engineering).

History of patients: recovered by electronic medical records (Axigate®).

Bibliographical research: Pubmed database, guidelines of French learned societies, French competent authorities and European Crohn’s and Colitis Organisation.1

Results Between 1 March 2016 and 1 March 2017, 76 patients were treated by a biotherapy for Crohn’s disease. Fifty-one patients had ‘in-label’ prescriptions. Twenty-five patients had ‘off-label’ prescriptions (increase in infliximab dose or frequency, use of golimumab because of therapeutic failure). The history of 76 patients showed that 43 patients received only one biotherapy since initiation. Thirty-three patients had a switch of biotherapy due to therapeutic failure (66%) or intolerance (34%). First-line patients were treated by infliximab (42), adalimumab (33) and golimumab (one). In the second line, patients were treated by infliximab (16), adalimumab (12), vedolizumab (four) or golimumab (one). In the third line, patients received vedolizumab (six), infliximab (one) and golimumab (one).

Conclusion In this study, infliximab and adalimumab are the most used biotherapies for Crohn’s disease in the first line and in the second line as recommended in the European guidelines.1 ‘Off label’ prescriptions of infliximab follow the French and European guidelines1 that support an increase in dose or administration frequency to improve pharmacokinetics. Vedolizumab use after failure of anti-TNF therapies, as recommended in European guidelines, is increasing due to its original mechanism of action (anti-integrin antibody). In spite of the therapeutic arsenal, there are still uncontrolled patients. In November 2016, ustekinumab has been approved in France and other drugs are currently in clinical trials. Thus, therapeutic strategy should be updated in the following years.

Reference and/or Acknowledgements 1. Gomollon F, et al. J Crohns Colitis2017Jan;11(1):3–25.

No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.